RemeGen’s RC118 Receives Orphan Drug Designations for Gastric and Pancreatic Cancers
China-based RemeGen Ltd announced that its antibody drug conjugate (ADC) drug candidate RC118 has obtained...
Innovent Biologics Presents Clinical Study Results at ESMO-IO 2022
China-based Innovent Biologics Inc. (HKG: 1801) announced the presentation of two clinical studies at the...
NMPA Extends Validation Period for COVID-19 Antigen Detection Reagents
The National Medical Products Administration released a notification extending the validation period of approvals for...
Science Standard Medical Testing Raises Pre-Series A Funding
Science Standard Medical Testing, a professional third-party testing institution based in Changzhou, reportedly raised “tens...
Phanes Therapeutics and BeiGene Partner on Phase I Study of PT199
Sino-US biotech Phanes Therapeutics Inc. announced a clinical study cooperation and supply agreement with China-based...
XtalPi Partners with CTTQ for AI-Driven Small-Molecule Drug Development
Sino-US artificial intelligence (AI) firm XtalPi Inc. struck a partnership with China-based Jiangsu Chia Tai...
Harbour BioMed Concludes Phase I Study for HBM4003 in Advanced Melanoma
Harbour BioMed (HBM; HKG: 2142), a biotech operating out of the United States, the Netherlands,...
Frontier Biotechnologies Partners with Yuyue Med for FB2001 Atomizer
China-based Frontier Biotechnologies Inc. (SHA: 688221) announced a strategic collaboration agreement with compatriot firm Jiangsu...
Harbour BioMed’s Nona Biosciences Licenses Antibody Platform to Kelun-Biotech
Harbour BioMed (HKG: 2142), a biotech operating out of the Netherlands, the United States, and...
ExoNeuglia Secures Angel Funding for iPSC-Based Cell Therapy
ExoNeuglia, a stem-cell-focused biotech based in Suzhou, reportedly raised “tens of millions” of renminbi in...
Jacobio’s KRAS G12C Inhibitor JAB-21822 Receives Breakthrough Therapy Designation
The Center for Drug Evaluation (CDE) website indicates that China-based Jacobio Pharmaceuticals Group Co., Ltd’s...
CSPC and Ascletis Get NMPA Approval for COVID-19 Drug Clinical Trials
China-based firms CSPC Pharmaceutical Group Ltd (HKG: 1093) and Ascletis Pharma Inc. (HKG: 1672) both...
24 Provinces Form Alliances for Volume-Based Procurement of Medical Consumables
The Henan provincial alliance procurement office released a notification indicating that 24 provinces/regions will form...
Yuanmai Cell Biotechnology Secures Angel Funding for Macrophage Immunotherapy
Yuanmai Cell Biotechnology Co., Ltd, a macrophage immunotherapy developer based in Nanjing, reportedly raised “tens...
Yantai Dongcheng Pharma Acquires Rights to 18F-APN-1607 from Aprinoia Therapeutics
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced the plan to acquire the...
Shanghai Hantong Medtech Raises Angel Funding for Ultrasound Platform
Shanghai Hantong Medical Technology Co., Ltd reportedly raised “tens of millions” of renminbi in an...
GenAssist Therapeutics Secures Series A Funding for Gene Therapy Development
China’s Suzhou GenAssist Therapeutics Co., Ltd, a base editing technology-based gene therapy developer, reportedly raised...
Hansoh’s Generic Firazyr Approved for Marketing in China by NMPA
The National Medical Products Administration (NMPA) website indicates that China-based Hansoh Pharmaceutical Group Co., Ltd’s...
NMPA Approves Viatris’ Symfi Lo for HIV-1 Treatment in China
The National Medical Products Administration (NMPA) website indicates that US-based Viatris Inc.’s (NASDAQ: VTRS) Symfi...
SciClone’s Danyelza Approved for Marketing in China by NMPA
The National Medical Products Administration (NMPA) website indicates that SciClone Pharmaceuticals Inc’s (Nasdaq: SCLN) Danyelza...